Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

Rhea-AI Summary

Prelude Therapeutics (Nasdaq: PRLD) announced FDA clearance of its IND for PRT12396, a mutant-selective JAK2V617F inhibitor, enabling a Phase 1 open-label study in high-risk polycythemia vera and intermediate/high-risk myelofibrosis.

The company anticipates dosing the first patient by Q2 2026 and notes an exclusive option agreement with Incyte from November 2025.

Positive

• FDA cleared IND for PRT12396 enabling clinical development
• Phase 1 study targeting PV and MF expected to start Q2 2026
• Exclusive option agreement with Incyte announced November 2025
• Preclinical data show mutant-selective JAK2V617F inhibition in models

Negative

• PRT12396 remains early-stage with no human efficacy data
• Primary endpoints are safety and PK, efficacy unproven
• Clinical risk and timeline uncertainty inherent to Phase 1 studies

News Market Reaction – PRLD

+12.81% 1.5x vol

6 alerts

+12.81% News Effect

+4.8% Peak Tracked

-9.2% Trough Tracked

+$17M Valuation Impact

$147M Market Cap

1.5x Rel. Volume

On the day this news was published, PRLD gained 12.81%, reflecting a significant positive market reaction. Argus tracked a peak move of +4.8% during that session. Argus tracked a trough of -9.2% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $17M to the company's valuation, bringing the market cap to $147M at that time. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

First patient dosing target: Q2 2026 PV JAK2V617F prevalence: 95% ET JAK2V617F prevalence: 60% +2 more

5 metrics

First patient dosing target Q2 2026 Anticipated first patient dosing for PRT12396 Phase 1 study

PV JAK2V617F prevalence 95% Proportion of polycythemia vera patients with JAK2V617F mutation

ET JAK2V617F prevalence 60% Proportion of essential thrombocythemia patients with JAK2V617F mutation

MF JAK2V617F prevalence 55% Proportion of myelofibrosis patients with JAK2V617F mutation

Phase Phase 1 Planned first-in-human study of PRT12396 in PV and MF

Market Reality Check

Price: $3.12 Vol: Volume 119,308 is below t...

low vol

$3.12 Last Close

Volume Volume 119,308 is below the 20-day average of 477,769 (relative volume 0.25). low

Technical Shares trade above the 200-day MA, with price at 2.03 vs MA200 of 1.32.

Peers on Argus

PRLD showed an upward move pre-news (+9.73%) while peers were mixed: ANL gained ...

1 Up

PRLD showed an upward move pre-news (+9.73%) while peers were mixed: ANL gained 9.96%, BYSI and ACET were modestly positive, INKT declined, and OSTX inched higher. With only one peer in momentum and no consistent direction across names, the setup points to company‑specific drivers rather than a broad biotech rotation.

Common Catalyst A peer (ANL) reported a private placement, but no shared clinical or FDA-related theme appears across the small peer set.

Historical Context

5 past events · Latest: Nov 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 12	Earnings and update	Positive	+8.9%	Q3 2025 results, cash runway into 2027, pipeline timing reaffirmed.
Nov 04	Strategic update	Positive	-55.8%	Incyte option economics, KAT6A prioritization, SMARCA2 pause, cash runway.
Nov 04	Incyte option deal	Positive	-55.8%	Exclusive JAK2V617F option with up to $910M potential payments.
Nov 03	ASH abstracts	Positive	+150.3%	Preclinical JAK2V617F data and mCALR DACs for MPNs ahead of ASH.
Oct 17	Board change	Neutral	-9.2%	Director resignation and new Audit Committee chair appointment.

Pattern Detected

News impact has been inconsistent: clinical/abstract updates and standard earnings skew positive, while strategic deal announcements and governance changes have seen sharp or notable drawdowns.

Recent Company History

Over the last few months, Prelude has transformed around its JAK2V617F and KAT6A programs. On Nov 3, 2025, preclinical data for JAK2V617F inhibitors and mCALR‑targeted DACs coincided with a 150.31% move. The Nov 4, 2025 exclusive option deal with Incyte and strategic business update added substantial potential milestones but the stock dropped about 55%. Q3 2025 earnings on Nov 12, 2025 highlighted $58.2M cash and rising revenue with an 8.89% gain. Today’s IND clearance advances the same JAK2V617F platform into Phase 1, extending this clinical progression theme.

Market Pulse Summary

The stock surged +12.8% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +12.8% in the session following this news. A strong positive reaction aligns with the IND clearance for PRT12396 and advances in the JAK2V617F program. Past JAK2- and ASH-related catalysts saw significant moves, including a 150.31% jump on preclinical abstracts, while some strategic deal news sold off. Investors have previously rewarded clear clinical progression, but sharp divergences around partnership announcements highlight risk that enthusiasm could fade if subsequent data or strategy updates disappoint.

Key Terms

investigational new drug application (ind), jak2v617f, myeloproliferative neoplasms (mpns), polycythemia vera, +4 more

8 terms

investigational new drug application (ind) regulatory

"FDA cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND)"

An investigational new drug application (IND) is a formal request made to regulatory authorities to begin testing a new medicine in humans. It is a crucial step in the drug development process, allowing companies to conduct clinical trials to determine if the drug is safe and effective. For investors, an IND signals progress in the drug's development, which can influence a company's potential growth and valuation.

jak2v617f medical

"PRT12396, a mutant-selective JAK2V617F inhibitor being developed for the treatment"

A specific, single-letter change in the JAK2 gene that makes a cell’s growth-control switch stay stuck in the “on” position, driving overproduction of blood cells. Think of it like a thermostat jammed at a high setting; it’s a clear biological marker used to diagnose and classify certain blood cancers, guide use of targeted drugs and tests, and influence which treatments or diagnostics reach the market and how large those markets may be.

myeloproliferative neoplasms (mpns) medical

"for the treatment of patients with certain myeloproliferative neoplasms (MPNs)"

Myeloproliferative neoplasms (MPNs) are a group of chronic blood cancers in which the bone marrow makes too many blood cells, upsetting normal circulation and causing symptoms such as fatigue, bruising, clotting or organ enlargement. They matter to investors because treatments are usually long-term and many patients lack fully effective therapies, so successful drugs, diagnostics or regulatory approvals can produce steady revenues or sharply change a company's value—like winning a durable, niche market where clinical and safety results drive investor decisions.

polycythemia vera medical

"Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis"

A rare, long-term blood disorder in which the body makes too many red blood cells, thickening the blood and raising the risk of clots, bleeding, fatigue and other complications. Think of it like a faucet left partially open that slowly overfills a sink — the excess cells create strain and danger over time. Investors care because the condition drives demand for diagnostics, treatments and ongoing care, influences clinical trial and regulatory outcomes, and can affect revenue and costs for drugmakers, hospitals and insurers.

myelofibrosis medical

"patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026"

A bone marrow disorder in which healthy, spongy marrow is gradually replaced by scar tissue, like a garden soil turned to concrete so seeds can’t grow. That replacement reduces production of red and white blood cells and platelets, causing anemia, fatigue, infections and an enlarged spleen. Investors care because the condition creates demand for therapies, clinical trials and regulatory decisions that can materially affect drug sales and company valuations.

essential thrombocythemia medical

"60% of patients with essential thrombocythemia (ET) and 55% of patients with myelofibrosis"

Essential thrombocythemia is a chronic blood disorder in which the body produces too many platelets, the cells that help blood clot; this imbalance raises the risk of dangerous clots, bleeding, and long-term complications such as stroke or heart attack. It matters to investors because it creates demand for long-term therapies, affects clinical trial design and regulatory review for new drugs, and can influence a company’s revenue and risk profile if treatments prove effective or face safety challenges.

allosteric inhibitors medical

"Prelude has designed and identified novel allosteric inhibitors that bind into the JAK2 JH2"

Allosteric inhibitors are drugs or molecules that attach to a spot on a protein separate from its active site and change the protein’s shape so it works less effectively, like pressing a side button on a device to make it slow down. For investors, they matter because this approach can produce more selective, potentially safer therapies, create new intellectual property around hard-to-target molecules, and open alternative paths when direct-blocking drugs fail or cause resistance.

mutant allele burden medical

"may have the potential to reduce mutant allele burden, slow or even reverse disease progression"

Mutant allele burden is the proportion of DNA in a tissue or blood sample that carries a specific genetic change, showing how many cells in a sample bear that mutation. It matters to investors because higher or rising levels can signal a larger population of diseased cells, affect how well a drug or test works, and influence clinical outcomes and market potential; imagine it as the share of cars in a parking lot with the same visible defect.

AI-generated analysis. Not financial advice.

Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026

WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT12396, a mutant-selective JAK2V617F inhibitor being developed for the treatment of patients with certain myeloproliferative neoplasms (MPNs). The Company anticipates dosing the first patient by Q2 of 2026.

“The FDA’s clearance of our IND for PRT12396 marks a pivotal first milestone in the strategic transformation and development focus on our JAK2 and KAT6 programs that we outlined last quarter,” stated Kris Vaddi, Chief Executive Officer of Prelude. “This achievement demonstrates our ability to translate high-quality science rapidly into clinical progress and our clear focus on executing these programs that represent the potential to reshape the treatment landscape for the target patient populations. We look forward to advancing PRT12396 into the phase 1 study in patients with polycythemia vera and myelofibrosis in parallel.”

The Phase 1 study of PRT12396 is an open-label, multi-center, safety and efficacy study in patients with high-risk polycythemia vera (PV) and intermediate and high-risk myelofibrosis (MF). The primary endpoints of the study include safety, efficacy and PK profile.

The JAK2V617F inhibitor program is subject to an exclusive option agreement with Incyte announced in November 2025.

Mutant selective JAK2V617F JH2 inhibitor program
JAK2V617F is the primary driver mutation responsible for disease progression in the majority of patients living with myeloproliferative neoplasms (MPNs). The mutation impacts approximately 95% of patients with polycythemia vera (PV), 60% of patients with essential thrombocythemia (ET) and 55% of patients with myelofibrosis (MF). Identifying JAK2 JH2 inhibitors that selectively target V617F+ cells has long been the goal for advancing the treatment of MPNs. Prelude has designed and identified novel allosteric inhibitors that bind into the JAK2 JH2 “deep pocket” where the V617F mutation resides. These candidates demonstrate mutant specific inhibition in multiple preclinical models of MPNs. Prelude believes this approach may have the potential to reduce mutant allele burden, slow or even reverse disease progression, and transform treatment outcomes for MPN patients.

About Prelude Therapeutics 
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline features highly selective KAT6A degraders and JAK2V617F mutant selective inhibitors -- new approaches to clinically validated targets with transformative potential for patients. We are leveraging our expertise in targeted protein degradation to create and develop next generation degrader antibody conjugates (DACs) with novel payloads. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.

Cautionary Note Regarding Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Prelude’s product candidates, the potential safety, efficacy, benefits and addressable market for Prelude’s product candidates, the expected timeline for clinical trial results for Prelude’s product candidates, and the sufficiency of Prelude’s cash runway. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” “schedule,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company’s current expectations and projections about future events and various assumptions. Although Prelude believes that the expectations reflected in such forward-looking statements are reasonable, Prelude cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Prelude's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Prelude's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Prelude’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Prelude's ability to fund development activities and achieve development goals, Prelude's ability to protect intellectual property, and other risks and uncertainties described under the heading "Risk Factors" in Prelude’s Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Reports on Form 10-Q and other documents that Prelude files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Prelude undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law.  

Investor Contact: 
Robert A. Doody, Jr.
Senior Vice President, Investor Relations
Prelude Therapeutics Incorporated 
484.639.7235
rdoody@preludetx.com

FAQ

What did Prelude Therapeutics announce about PRT12396 and the IND on February 3, 2026 (PRLD)?

They announced FDA clearance of an IND for PRT12396, a JAK2V617F inhibitor, enabling a Phase 1 study. According to the company, first patient dosing is anticipated by Q2 2026 and the trial will enroll PV and MF patients.

When will Prelude (PRLD) begin dosing patients in the Phase 1 PRT12396 study?

Dosing is expected to begin by Q2 2026 for the Phase 1 study. According to the company, the trial is open-label, multi-center, and will evaluate safety, efficacy and pharmacokinetics in PV and MF patients.

What patient populations will Prelude's PRT12396 Phase 1 trial (PRLD) include?

The trial will enroll patients with high-risk polycythemia vera and intermediate or high-risk myelofibrosis. According to the company, the study is designed to assess safety, efficacy and the PK profile in these MPN populations.

What is the mechanism and selectivity claim for PRT12396 from Prelude (PRLD)?

PRT12396 is described as a mutant-selective JAK2V617F JH2 allosteric inhibitor targeting the V617F mutation pocket. According to the company, preclinical models show mutant-specific inhibition that may reduce mutant allele burden.

How does Prelude's partnership with Incyte relate to the JAK2 program (PRLD)?

The JAK2V617F program is subject to an exclusive option agreement with Incyte announced in November 2025. According to the company, the agreement provides Incyte an option related to the mutant-selective JAK2 program.